Although considered as a single biomarker, TERT promoter mutations do not seem ideal for HCC screening, the detection of these mutations in liquid biopsy, in conjunction with other genetic or epigenetic biomarkers, could define better the premalignant state, indicating a subgroup of patients in which aggressive surveillance for HCC is mandatory. The gene discussed is TERT; the disease is hepatocellular carcinoma.